Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
14.91
-0.31 (-2.04%)
Mar 6, 2026, 9:59 AM EST - Market open
Nurix Therapeutics Income Statement
Financials in millions USD. Fiscal year is December - November.
Millions USD. Fiscal year is Dec - Nov.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Nov '25 Nov 30, 2025 | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 |
| Revenue | 83.98 | 54.55 | 76.99 | 38.63 | 29.75 | |
| Revenue Growth (YoY) | 53.95% | -29.14% | 99.31% | 29.84% | 66.95% | |
| Cost of Revenue | 316.9 | 221.63 | 189.15 | 184.5 | 116.43 | |
| Gross Profit | -232.92 | -167.08 | -112.16 | -145.87 | -86.68 | |
| Selling, General & Admin | 52.74 | 45.94 | 42.9 | 38 | 31.2 | |
| Operating Expenses | 52.74 | 45.94 | 42.9 | 38 | 31.2 | |
| Operating Income | -285.67 | -213.03 | -155.06 | -183.87 | -117.89 | |
| Interest & Investment Income | 21.97 | 19.73 | 11.12 | 3.51 | 0.82 | |
| Pretax Income | -263.7 | -193.3 | -143.95 | -180.36 | -117.06 | |
| Income Tax Expense | 0.76 | 0.27 | - | - | 0.13 | |
| Net Income | -264.46 | -193.57 | -143.95 | -180.36 | -117.19 | |
| Net Income to Common | -264.46 | -193.57 | -143.95 | -180.36 | -117.19 | |
| Shares Outstanding (Basic) | 87 | 67 | 54 | 49 | 43 | |
| Shares Outstanding (Diluted) | 87 | 67 | 54 | 49 | 43 | |
| Shares Change (YoY) | 29.12% | 23.52% | 11.79% | 13.32% | 173.68% | |
| EPS (Basic) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | |
| EPS (Diluted) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | |
| Free Cash Flow | -263.47 | -181.86 | -89.77 | -172.05 | -90.03 | |
| Free Cash Flow Per Share | -3.04 | -2.71 | -1.65 | -3.54 | -2.10 | |
| Gross Margin | -277.36% | - | -145.69% | - | -291.38% | |
| Operating Margin | -340.16% | -390.52% | -201.41% | -476.01% | -396.25% | |
| Profit Margin | -314.90% | -354.85% | -186.98% | -466.93% | -393.93% | |
| Free Cash Flow Margin | -313.73% | -333.38% | -116.60% | -445.42% | -302.61% | |
| EBITDA | -277.53 | -205.01 | -148.93 | -179.72 | -115.9 | |
| EBITDA Margin | - | - | -193.45% | - | - | |
| D&A For EBITDA | 8.14 | 8.02 | 6.13 | 4.15 | 1.99 | |
| EBIT | -285.67 | -213.03 | -155.06 | -183.87 | -117.89 | |
| EBIT Margin | - | - | -201.41% | - | - | |
| Revenue as Reported | 83.98 | 54.55 | 76.99 | 38.63 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.